

**TDMS No.** 99023 - 04  
**Test Type:** CHRONIC  
**Route:** GAVAGE  
**Species/Strain:** MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

beta-Myrcene  
**CAS Number:** 123-35-3

**Date Report Requested:** 07/26/2007  
**Time Report Requested:** 09:29:40  
**First Dose M/F:** 04/11/02 / 04/10/02  
**Lab:** BAT

F1\_M3

**C Number:** C99023  
**Lock Date:** 12/22/2004  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**TDMSE Version:** 1.8.0

TDMS No. 99023 - 04  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

beta-Myrcene  
 CAS Number: 123-35-3

Date Report Requested: 07/26/2007  
 Time Report Requested: 09:29:40  
 First Dose M/F: 04/11/02 / 04/10/02  
 Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident				3
Moribund Sacrifice	7	6	8	12
Natural Death	8	9	11	14
Survivors				
Natural Death	1			
Terminal Sacrifice	34	35	31	21
Animals Examined Microscopically	50	50	50	50

**ALIMENTARY SYSTEM**

Esophagus	(50)	(50)	(50)	(49)
Inflammation	2 (4%)	6 (12%)	3 (6%)	8 (16%)
Necrosis				5 (10%)
Muscularis, Degeneration		3 (6%)		
Gallbladder	(49)	(49)	(49)	(49)
Intestine Large, Cecum	(49)	(48)	(49)	(47)
Edema			1 (2%)	
Lymphoid Tissue, Hyperplasia		2 (4%)		
Intestine Small, Duodenum	(49)	(47)	(47)	(48)
Inflammation, Chronic Active				1 (2%)
Necrosis				2 (4%)
Intestine Small, Ileum	(49)	(47)	(47)	(47)
Intestine Small, Jejunum	(49)	(47)	(49)	(45)
Peyer's Patch, Hyperplasia, Lymphoid			2 (4%)	
Liver	(50)	(50)	(50)	(50)
Abscess				1 (2%)
Amyloid Deposition	1 (2%)		1 (2%)	
Angiectasis		1 (2%)	2 (4%)	
Basophilic Focus	3 (6%)	7 (14%)	6 (12%)	2 (4%)
Clear Cell Focus	15 (30%)	21 (42%)	21 (42%)	2 (4%)
Degeneration, Cystic			1 (2%)	
Eosinophilic Focus	16 (32%)	23 (46%)	21 (42%)	18 (36%)
Fatty Change	25 (50%)	18 (36%)	16 (32%)	29 (58%)
Hematopoietic Cell Proliferation	3 (6%)	2 (4%)	2 (4%)	1 (2%)
Infarct		2 (4%)		
Inflammation, Chronic Active	26 (52%)	24 (48%)	23 (46%)	17 (34%)
Mineralization			2 (4%)	7 (14%)
Mixed Cell Focus	13 (26%)	3 (6%)	6 (12%)	3 (6%)
Necrosis	7 (14%)	10 (20%)	13 (26%)	17 (34%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Pigmentation, Ceroid	1 (2%)			
Pigmentation, Hemosiderin	2 (4%)	4 (8%)		2 (4%)
Tension Lipidosis	3 (6%)	5 (10%)	4 (8%)	7 (14%)
Thrombosis	1 (2%)			
Vacuolization Cytoplasmic	3 (6%)	3 (6%)	4 (8%)	23 (46%)
Hepatocyte, Hypertrophy	1 (2%)	2 (4%)	16 (32%)	38 (76%)
Hepatocyte, Pigmentation, Hemosiderin			1 (2%)	
Oval Cell, Hyperplasia		3 (6%)	2 (4%)	
Mesentery	(4)	(7)	(5)	(3)
Necrosis		1 (14%)		
Fat, Necrosis	4 (100%)	5 (71%)	4 (80%)	2 (67%)
Pancreas	(50)	(50)	(50)	(50)
Atrophy	1 (2%)	1 (2%)		2 (4%)
Cytoplasmic Alteration	1 (2%)		1 (2%)	2 (4%)
Inflammation				1 (2%)
Necrosis, Focal				1 (2%)
Duct, Cyst				1 (2%)
Salivary Glands	(50)	(50)	(50)	(50)
Inflammation	1 (2%)		1 (2%)	1 (2%)
Stomach, Forestomach	(50)	(50)	(49)	(50)
Inflammation	10 (20%)	9 (18%)	13 (27%)	23 (46%)
Mineralization	1 (2%)			
Necrosis	1 (2%)	1 (2%)	1 (2%)	6 (12%)
Ulcer	4 (8%)	4 (8%)	7 (14%)	9 (18%)
Epithelium, Hyperplasia	12 (24%)	17 (34%)	16 (33%)	28 (56%)
Epithelium, Metaplasia			1 (2%)	
Stomach, Glandular	(50)	(50)	(50)	(50)
Dysplasia	1 (2%)			
Hyperplasia	2 (4%)	1 (2%)	1 (2%)	2 (4%)
Inflammation	1 (2%)		1 (2%)	2 (4%)
Metaplasia, Squamous		1 (2%)	1 (2%)	1 (2%)
Necrosis			1 (2%)	2 (4%)
Muscularis, Hypertrophy	1 (2%)			
Tongue	(1)	(0)	(0)	(0)
Tooth	(38)	(33)	(35)	(13)
Dysplasia	38 (100%)	31 (94%)	35 (100%)	13 (100%)
Gingiva, Inflammation	1 (3%)			
Peridontal Tissue, Inflammation	1 (3%)	1 (3%)		
Pulp, Inflammation	1 (3%)	3 (9%)	1 (3%)	
<b>CARDIOVASCULAR SYSTEM</b>				
Blood Vessel	(0)	(2)	(1)	(2)
Mineralization		1 (50%)		
Heart	(50)	(50)	(50)	(50)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Cardiomyopathy	15 (30%)	12 (24%)	13 (26%)	19 (38%)
Fibrosis		1 (2%)		
Inflammation	2 (4%)	1 (2%)		
Mineralization	2 (4%)	1 (2%)	4 (8%)	7 (14%)
Necrosis		1 (2%)		
Atrium, Thrombosis	1 (2%)		2 (4%)	1 (2%)
Coronary Artery, Inflammation	3 (6%)			
Vein, Venule, Thrombosis		1 (2%)		
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(50)	(50)	(50)
Amyloid Deposition	1 (2%)			
Hypertrophy	7 (14%)	4 (8%)	10 (20%)	
Necrosis				1 (2%)
Thrombosis			1 (2%)	
Subcapsular, Hyperplasia	46 (92%)	47 (94%)	46 (92%)	43 (86%)
Zona Fasciculata, Atrophy		1 (2%)		
Zona Fasciculata, Hyperplasia		1 (2%)	3 (6%)	2 (4%)
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	1 (2%)	2 (4%)		
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	38 (76%)	36 (72%)	28 (56%)	18 (36%)
Infiltration Cellular, Mixed Cell			1 (2%)	
Pituitary Gland	(49)	(49)	(50)	(49)
Pars Distalis, Hyperplasia	1 (2%)	1 (2%)		
Thyroid Gland	(50)	(50)	(50)	(50)
Inflammation				1 (2%)
Mineralization	1 (2%)			
C-cell, Hyperplasia	1 (2%)		1 (2%)	1 (2%)
Follicle, Cyst	1 (2%)	3 (6%)		1 (2%)
Follicle, Degeneration	1 (2%)	1 (2%)		2 (4%)
Follicular Cell, Hyperplasia		4 (8%)		2 (4%)
Follicular Cell, Hypertrophy	1 (2%)	1 (2%)		
<b>GENERAL BODY SYSTEM</b>				
None				
<b>GENITAL SYSTEM</b>				
Epididymis	(50)	(50)	(50)	(50)
Cyst	1 (2%)		1 (2%)	

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Fibrosis	1 (2%)			
Granuloma Sperm	1 (2%)			
Inflammation			2 (4%)	
Mineralization				1 (2%)
Preputial Gland	(50)	(50)	(50)	(50)
Ectasia	4 (8%)	5 (10%)	4 (8%)	3 (6%)
Inflammation	5 (10%)	3 (6%)	2 (4%)	2 (4%)
Prostate	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	
Hyperplasia		2 (4%)		
Inflammation	25 (50%)	15 (30%)	22 (44%)	12 (24%)
Seminal Vesicle	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	
Inflammation			1 (2%)	
Testes	(50)	(50)	(50)	(50)
Germinal Epithelium, Degeneration	5 (10%)	2 (4%)	5 (10%)	18 (36%)
Germinal Epithelium, Mineralization			2 (4%)	2 (4%)

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)
Atrophy	1 (2%)		1 (2%)	18 (36%)
Myelofibrosis	1 (2%)		1 (2%)	1 (2%)
Necrosis, Focal		1 (2%)		
Pigmentation		1 (2%)	1 (2%)	1 (2%)
Myeloid Cell, Hyperplasia	1 (2%)	3 (6%)	3 (6%)	1 (2%)
Lymph Node	(2)	(0)	(5)	(1)
Inguinal, Atrophy			1 (20%)	
Inguinal, Infiltration Cellular, Histiocyte			1 (20%)	
Mediastinal, Inflammation, Granulomatous			1 (20%)	
Lymph Node, Mandibular	(49)	(50)	(48)	(49)
Atrophy	3 (6%)	6 (12%)	9 (19%)	23 (47%)
Hyperplasia, Lymphoid		3 (6%)	2 (4%)	
Infiltration Cellular, Plasma Cell	1 (2%)	3 (6%)	1 (2%)	
Lymph Node, Mesenteric	(49)	(50)	(47)	(44)
Amyloid Deposition	1 (2%)			
Atrophy	12 (24%)	12 (24%)	13 (28%)	28 (64%)
Hyperplasia, Lymphoid		2 (4%)	1 (2%)	
Infiltration Cellular, Plasma Cell		1 (2%)		
Inflammation	1 (2%)			
Inflammation, Granulomatous			1 (2%)	
Pigmentation, Hemosiderin	1 (2%)			
Spleen	(49)	(50)	(48)	(49)
Amyloid Deposition	1 (2%)		1 (2%)	
Hematopoietic Cell Proliferation	33 (67%)	43 (86%)	41 (85%)	10 (20%)

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Hyperplasia, Lymphoid Infiltration Cellular, Histiocyte Pigmentation, Hemosiderin	1 (2%)		1 (2%)	2 (4%)
Lymphoid Follicle, Atrophy	7 (14%)	5 (10%)	10 (21%)	31 (63%)
Lymphoid Follicle, Hyperplasia			1 (2%)	
Thymus	(47)	(47)	(48)	(47)
Amyloid Deposition	1 (2%)			
Atrophy	45 (96%)	40 (85%)	44 (92%)	41 (87%)
Hyperplasia, Lymphoid Infiltration Cellular, Plasma Cell Necrosis				1 (2%) 1 (2%) 1 (2%)
<b>INTEGUMENTARY SYSTEM</b>				
Skin	(50)	(50)	(50)	(50)
Infiltration Cellular, Mast Cell, Focal Inflammation	1 (2%)	1 (2%)	2 (4%)	
Ulcer	1 (2%)	2 (4%)	3 (6%)	
Hair Follicle, Inflammation	1 (2%)			
Sebaceous Gland, Hyperplasia				1 (2%)
Subcutaneous Tissue, Edema			1 (2%)	
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(50)	(50)
Fibrous Osteodystrophy				1 (2%)
Osteoporosis		1 (2%)		
Joint, Arthrosis	1 (2%)			
Skeletal Muscle	(0)	(2)	(1)	(1)
Inflammation		1 (50%)		1 (100%)
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Vein, Infiltration Cellular, Lymphocyte			1 (2%)	
Peripheral Nerve	(0)	(0)	(1)	(0)
Infiltration Cellular, Lymphocyte			1 (100%)	
Spinal Cord	(0)	(0)	(1)	(0)
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(50)	(50)

TDMS No. 99023 - 04  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

beta-Myrcene  
 CAS Number: 123-35-3

Date Report Requested: 07/26/2007  
 Time Report Requested: 09:29:40  
 First Dose M/F: 04/11/02 / 04/10/02  
 Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Abscess				1 (2%)
Foreign Body				1 (2%)
Hematopoietic Cell Proliferation			1 (2%)	
Inflammation, Suppurative			1 (2%)	1 (2%)
Inflammation, Chronic Active	2 (4%)	1 (2%)	1 (2%)	3 (6%)
Thrombosis			1 (2%)	1 (2%)
Alveolar Epithelium, Hyperplasia	4 (8%)	8 (16%)	5 (10%)	5 (10%)
Alveolus, Infiltration Cellular, Histiocyte	4 (8%)	9 (18%)	1 (2%)	3 (6%)
Arteriole, Degeneration		1 (2%)		
Bronchiole, Hyperplasia	1 (2%)	2 (4%)		1 (2%)
Glands, Inflammation		2 (4%)	1 (2%)	
Nose	(50)	(50)	(50)	(50)
Inflammation	3 (6%)	2 (4%)	2 (4%)	3 (6%)
Polyp, Inflammatory	6 (12%)			
Glands, Dilatation		3 (6%)	1 (2%)	
Olfactory Epithelium, Degeneration	5 (10%)	5 (10%)	7 (14%)	6 (12%)
Olfactory Epithelium, Metaplasia, Respiratory	7 (14%)	2 (4%)	1 (2%)	
Respiratory Epithelium, Hyperplasia	1 (2%)	1 (2%)		
<b>SPECIAL SENSES SYSTEM</b>				
Eye	(50)	(50)	(50)	(50)
Fibrosis			1 (2%)	
Thrombosis				1 (2%)
Cornea, Hyperplasia, Squamous		2 (4%)		
Cornea, Inflammation		2 (4%)		1 (2%)
Lens, Cataract		2 (4%)		
Optic Nerve, Fibrosis	1 (2%)	1 (2%)		
Retina, Degeneration		2 (4%)		
Harderian Gland	(50)	(50)	(50)	(50)
Fibrosis	1 (2%)	1 (2%)		
Hyperplasia	1 (2%)	3 (6%)	2 (4%)	2 (4%)
Inflammation				1 (2%)
<b>URINARY SYSTEM</b>				
Kidney	(50)	(50)	(50)	(50)
Accumulation, Hyaline Droplet			3 (6%)	
Infarct	6 (12%)	6 (12%)	7 (14%)	1 (2%)
Mineralization	31 (62%)	31 (62%)	29 (58%)	12 (24%)
Nephropathy	44 (88%)	44 (88%)	43 (86%)	27 (54%)
Cortex, Cyst	6 (12%)	6 (12%)	4 (8%)	3 (6%)
Cortex, Inflammation	1 (2%)	2 (4%)		
Cortex, Metaplasia, Osseous	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99023 - 04  
Test Type: CHRONIC  
Route: GAVAGE  
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

beta-Myrcene

CAS Number: 123-35-3

Date Report Requested: 07/26/2007  
Time Report Requested: 09:29:40  
First Dose M/F: 04/11/02 / 04/10/02  
Lab: BAT

---

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Papilla, Inflammation	1 (2%)	2 (4%)		1 (2%)
Papilla, Necrosis	1 (2%)	1 (2%)	1 (2%)	
Pelvis, Dilatation			1 (2%)	
Pelvis, Inflammation	1 (2%)		2 (4%)	
Renal Tubule, Hyperplasia	14 (28%)	16 (32%)	14 (28%)	6 (12%)
Renal Tubule, Necrosis			3 (6%)	18 (36%)
Renal Tubule, Pigmentation, Hemosiderin	1 (2%)	2 (4%)	1 (2%)	
Renal Tubule, Vacuolization Cytoplasmic	39 (78%)	41 (82%)	20 (40%)	
Urinary Bladder	(50)	(50)	(49)	(49)
Inflammation			1 (2%)	

---

\*\*\* END OF MALE \*\*\*

TDMS No. 99023 - 04  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

beta-Myrcene  
 CAS Number: 123-35-3

Date Report Requested: 07/26/2007  
 Time Report Requested: 09:29:40  
 First Dose M/F: 04/11/02 / 04/10/02  
 Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident		1	1	
Moribund Sacrifice	4	5	6	5
Natural Death	7	10	8	28
Survivors				
Terminal Sacrifice	39	34	35	17
Animals Examined Microscopically	50	50	50	50

**ALIMENTARY SYSTEM**

Esophagus	(50)	(50)	(50)	(50)
Inflammation	2 (4%)	1 (2%)	4 (8%)	
Necrosis			2 (4%)	
Muscularis, Degeneration	1 (2%)		1 (2%)	
Gallbladder	(47)	(50)	(50)	(49)
Intestine Large, Cecum	(49)	(50)	(50)	(47)
Edema			1 (2%)	
Inflammation			1 (2%)	
Epithelium, Metaplasia			1 (2%)	
Intestine Large, Colon	(50)	(50)	(50)	(47)
Parasite Metazoan				1 (2%)
Epithelium, Inflammation			1 (2%)	
Intestine Large, Rectum	(50)	(49)	(50)	(49)
Inflammation			1 (2%)	
Necrosis			1 (2%)	
Intestine Small, Jejunum	(50)	(48)	(49)	(40)
Peyer's Patch, Hyperplasia, Lymphoid			3 (6%)	
Serosa, Fibrosis		1 (2%)		
Liver	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)	1 (2%)	2 (4%)	
Basophilic Focus	2 (4%)	1 (2%)	4 (8%)	1 (2%)
Clear Cell Focus		1 (2%)	1 (2%)	
Cytoplasmic Alteration				1 (2%)
Eosinophilic Focus	4 (8%)	5 (10%)	6 (12%)	9 (18%)
Fatty Change	29 (58%)	35 (70%)	16 (32%)	15 (30%)
Hematopoietic Cell Proliferation	6 (12%)	1 (2%)	1 (2%)	1 (2%)
Infiltration Cellular, Lymphocyte		4 (8%)	1 (2%)	
Inflammation, Suppurative				1 (2%)
Inflammation, Chronic Active	43 (86%)	35 (70%)	34 (68%)	14 (28%)
Mineralization				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Mixed Cell Focus	1 (2%)	4 (8%)	6 (12%)	1 (2%)
Necrosis	3 (6%)	2 (4%)	3 (6%)	7 (14%)
Pigmentation, Hemosiderin	2 (4%)		2 (4%)	
Regeneration		1 (2%)		
Tension Lipidosis	12 (24%)	3 (6%)	10 (20%)	4 (8%)
Vacuolization Cytoplasmic	6 (12%)	11 (22%)	8 (16%)	30 (60%)
Bile Duct, Crystals			1 (2%)	
Bile Duct, Hyperplasia		1 (2%)	1 (2%)	
Hepatocyte, Hypertrophy			6 (12%)	40 (80%)
Oval Cell, Hyperplasia	1 (2%)		1 (2%)	
Mesentery	(15)	(18)	(3)	(0)
Fat, Necrosis	14 (93%)	15 (83%)	1 (33%)	
Pancreas	(50)	(49)	(50)	(48)
Atrophy	2 (4%)	1 (2%)	3 (6%)	1 (2%)
Basophilic Focus			1 (2%)	
Inflammation, Granulomatous			1 (2%)	
Mineralization				1 (2%)
Necrosis				1 (2%)
Acinus, Cytoplasmic Alteration, Focal		1 (2%)		
Duct, Cytoplasmic Alteration			1 (2%)	
Salivary Glands	(50)	(50)	(50)	(50)
Infiltration Cellular, Lymphocyte		1 (2%)		
Stomach, Forestomach	(50)	(49)	(50)	(47)
Inflammation	2 (4%)	5 (10%)	8 (16%)	19 (40%)
Mineralization				1 (2%)
Necrosis			4 (8%)	6 (13%)
Ulcer	3 (6%)	2 (4%)	3 (6%)	8 (17%)
Epithelium, Hyperplasia	7 (14%)	10 (20%)	17 (34%)	24 (51%)
Stomach, Glandular	(50)	(50)	(50)	(49)
Cytoplasmic Alteration, Focal	1 (2%)			
Inflammation	1 (2%)			2 (4%)
Mineralization				1 (2%)
Necrosis				2 (4%)
Tooth	(1)	(3)	(4)	(0)
Dysplasia	1 (100%)	3 (100%)	4 (100%)	

CARDIOVASCULAR SYSTEM

Blood Vessel	(2)	(2)	(2)	(1)
Inflammation, Chronic Active	1 (50%)			
Mineralization	1 (50%)	2 (100%)		
Aorta, Inflammation				1 (100%)
Carotid Artery, Intima, Hyperplasia			1 (50%)	
Media, Degeneration	1 (50%)			
Heart	(50)	(50)	(50)	(50)

TDMS No. 99023 - 04  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

beta-Myrcene

CAS Number: 123-35-3

Date Report Requested: 07/26/2007  
 Time Report Requested: 09:29:40  
 First Dose M/F: 04/11/02 / 04/10/02  
 Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Cardiomyopathy Degeneration	7 (14%)	1 (2%) 1 (2%)	4 (8%)	4 (8%)
Fibrosis			1 (2%)	1 (2%)
Inflammation	1 (2%)	2 (4%)		
Mineralization	1 (2%)	2 (4%)	2 (4%)	5 (10%)
Pigmentation, Hemosiderin		1 (2%)		
Atrium, Thrombosis			1 (2%)	
Coronary Artery, Inflammation	1 (2%)		1 (2%)	
Epicardium, Inflammation		1 (2%)		
Valve, Thrombosis	2 (4%)	2 (4%)		1 (2%)

**ENDOCRINE SYSTEM**

Adrenal Cortex	(50)	(50)	(50)	(50)
Hypertrophy			3 (6%)	
Capsule, Fibrosis		1 (2%)		
Capsule, Infiltration Cellular, Lymphocyte		1 (2%)		
Subcapsular, Hyperplasia	50 (100%)	50 (100%)	49 (98%)	50 (100%)
Zona Fasciculata, Hyperplasia	1 (2%)	2 (4%)		
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	1 (2%)	2 (4%)		
Parathyroid Gland	(47)	(34)	(43)	(44)
Cyst		1 (3%)		
Hyperplasia	1 (2%)			
Infiltration Cellular, Lymphocyte	1 (2%)			
Pituitary Gland	(50)	(50)	(50)	(50)
Pars Distalis, Hyperplasia	1 (2%)	2 (4%)	5 (10%)	2 (4%)
Pars Intermedia, Hyperplasia			1 (2%)	
Pars Nervosa, Inflammation		1 (2%)		
Thyroid Gland	(50)	(50)	(50)	(50)
Inflammation	2 (4%)	2 (4%)		1 (2%)
C-cell, Hyperplasia			1 (2%)	
Follicle, Cyst	1 (2%)	1 (2%)	3 (6%)	3 (6%)
Follicle, Degeneration	1 (2%)			
Follicular Cell, Hyperplasia	2 (4%)	1 (2%)	3 (6%)	

**GENERAL BODY SYSTEM**

None

**GENITAL SYSTEM**

Clitoral Gland	(49)	(48)	(50)	(49)
----------------	------	------	------	------

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Ovary	(50)	(50)	(49)	(49)
Amyloid Deposition			1 (2%)	
Angiectasis	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Atrophy	43 (86%)	44 (88%)	45 (92%)	43 (88%)
Hyperplasia, Tubular			1 (2%)	2 (4%)
Inflammation			1 (2%)	
Inflammation, Granulomatous		1 (2%)		
Thrombosis	1 (2%)			1 (2%)
Corpus Luteum, Cyst		2 (4%)	1 (2%)	
Follicle, Cyst	5 (10%)	4 (8%)	4 (8%)	
Follicle, Cyst, Multiple			1 (2%)	
Germinal Epithelium, Cyst	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Germinal Epithelium, Cyst, Multiple			1 (2%)	
Periovarian Tissue, Cyst		1 (2%)	1 (2%)	
Rete Ovarii, Cyst		1 (2%)		2 (4%)
Oviduct	(0)	(0)	(1)	(0)
Uterus	(50)	(50)	(50)	(50)
Angiectasis		1 (2%)	1 (2%)	2 (4%)
Thrombosis			1 (2%)	
Endometrium, Hyperplasia	43 (86%)	33 (66%)	28 (56%)	23 (46%)
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(49)	(49)	(50)
Atrophy	1 (2%)		7 (14%)	29 (58%)
Myelofibrosis	16 (32%)	9 (18%)	4 (8%)	3 (6%)
Necrosis		1 (2%)		
Myeloid Cell, Hyperplasia	2 (4%)	1 (2%)	1 (2%)	
Lymph Node	(7)	(8)	(7)	(0)
Bronchial, Hyperplasia, Lymphoid	1 (14%)		1 (14%)	
Inguinal, Infiltration Cellular, Plasma Cell	1 (14%)			
Renal, Amyloid Deposition	1 (14%)			
Renal, Ectasia	1 (14%)			
Renal, Infiltration Cellular, Plasma Cell	1 (14%)			
Lymph Node, Mandibular	(50)	(50)	(49)	(49)
Amyloid Deposition	1 (2%)			
Atrophy	4 (8%)	8 (16%)	11 (22%)	22 (45%)
Hyperplasia, Lymphoid	3 (6%)	2 (4%)	1 (2%)	1 (2%)
Infiltration Cellular, Plasma Cell	1 (2%)			
Lymph Node, Mesenteric	(47)	(48)	(44)	(39)
Atrophy	9 (19%)	7 (15%)	5 (11%)	25 (64%)
Hyperplasia, Lymphoid	1 (2%)			
Spleen	(49)	(50)	(50)	(50)
Amyloid Deposition	1 (2%)			
Hematopoietic Cell Proliferation	39 (80%)	39 (78%)	16 (32%)	11 (22%)

TDMS No. 99023 - 04  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

beta-Myrcene  
 CAS Number: 123-35-3

Date Report Requested: 07/26/2007  
 Time Report Requested: 09:29:40  
 First Dose M/F: 04/11/02 / 04/10/02  
 Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Hyperplasia, Lymphoid Infiltration Cellular, Plasma Cell	6 (12%)	4 (8%)	4 (8%)	1 (2%)
Pigmentation, Hemosiderin	1 (2%)	1 (2%)		
Lymphoid Follicle, Atrophy	9 (18%)	16 (32%)	11 (22%)	14 (28%)
Lymphoid Follicle, Hyperplasia	4 (8%)	11 (22%)	11 (22%)	32 (64%)
Thymus	(49)	(48)	(47)	(48)
Amyloid Deposition	1 (2%)			
Atrophy	22 (45%)	14 (29%)	19 (40%)	38 (79%)
Hyperplasia, Atypical Infiltration Cellular, Plasma Cell	1 (2%)	1 (2%)	1 (2%)	
Inflammation		1 (2%)		
<b>INTEGUMENTARY SYSTEM</b>				
Mammary Gland	(50)	(50)	(50)	(50)
Hyperplasia			1 (2%)	
Duct, Dilatation			1 (2%)	
Skin	(50)	(50)	(50)	(50)
Ulcer			1 (2%)	
Hair Follicle, Inflammation, Diffuse		1 (2%)		
Sebaceous Gland, Hyperplasia, Focal			1 (2%)	
Subcutaneous Tissue, Fibrosis	1 (2%)	1 (2%)		
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(50)	(50)
Joint, Degeneration	1 (2%)			
Tibia, Osteosclerosis	1 (2%)			
Skeletal Muscle	(0)	(3)	(0)	(0)
Inflammation		1 (33%)		
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Cerebellum, Necrosis			1 (2%)	
Cerebrum, Necrosis			1 (2%)	
Hippocampus, Necrosis			1 (2%)	
Medulla, Demyelination, Focal		1 (2%)		
Vein, Infiltration Cellular, Lymphocyte	1 (2%)		1 (2%)	
Peripheral Nerve	(0)	(1)	(0)	(0)
<b>RESPIRATORY SYSTEM</b>				

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Lung	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid Inflammation, Suppurative		1 (2%)		1 (2%)
Inflammation, Chronic Active	4 (8%)	1 (2%)	1 (2%)	3 (6%)
Pigmentation, Hemosiderin			1 (2%)	
Alveolar Epithelium, Hyperplasia	2 (4%)	3 (6%)	2 (4%)	5 (10%)
Alveolus, Infiltration Cellular, Histiocyte	5 (10%)		3 (6%)	1 (2%)
Bronchiole, Hyperplasia	1 (2%)	1 (2%)		1 (2%)
Serosa, Fibrosis, Focal	1 (2%)			
Serosa, Inflammation, Suppurative				1 (2%)
Nose	(50)	(50)	(50)	(50)
Olfactory Epithelium, Degeneration	2 (4%)	5 (10%)	5 (10%)	12 (24%)
Olfactory Epithelium, Metaplasia, Respiratory		1 (2%)		
Respiratory Epithelium, Hyperplasia	1 (2%)			
Trachea	(50)	(50)	(50)	(50)
Epithelium, Glands, Cytoplasmic Alteration			1 (2%)	

SPECIAL SENSES SYSTEM

Ear	(0)	(0)	(1)	(0)
Necrosis			1 (100%)	
Eye	(50)	(50)	(50)	(49)
Atrophy			1 (2%)	
Synechia	1 (2%)			
Cornea, Inflammation	1 (2%)	1 (2%)	1 (2%)	
Lens, Cataract			2 (4%)	
Retina, Retinal Detachment			1 (2%)	
Harderian Gland	(50)	(50)	(50)	(49)
Fibrosis	1 (2%)			
Hyperplasia	1 (2%)	2 (4%)	1 (2%)	

URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)
Accumulation, Hyaline Droplet				1 (2%)
Amyloid Deposition		1 (2%)	1 (2%)	
Infarct	4 (8%)	4 (8%)	3 (6%)	1 (2%)
Infiltration Cellular, Lymphocyte	1 (2%)	3 (6%)	4 (8%)	
Mineralization	10 (20%)	13 (26%)	8 (16%)	8 (16%)
Nephropathy	20 (40%)	21 (42%)	16 (32%)	16 (32%)
Cortex, Cyst	1 (2%)			
Cortex, Metaplasia, Osseous		2 (4%)		
Glomerulus, Amyloid Deposition	1 (2%)			
Papilla, Inflammation	1 (2%)	2 (4%)		2 (4%)

TDMS No. 99023 - 04  
Test Type: CHRONIC  
Route: GAVAGE  
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

beta-Myrcene

CAS Number: 123-35-3

Date Report Requested: 07/26/2007  
Time Report Requested: 09:29:40  
First Dose M/F: 04/11/02 / 04/10/02  
Lab: BAT

---

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Papilla, Necrosis	2 (4%)		1 (2%)	
Pelvis, Dilatation			1 (2%)	
Renal Tubule, Hyperplasia		1 (2%)	1 (2%)	
Renal Tubule, Necrosis	2 (4%)	2 (4%)	2 (4%)	17 (34%)
Ureter	(0)	(0)	(1)	(0)
Urinary Bladder	(50)	(50)	(50)	(49)
Infiltration Cellular, Lymphocyte	1 (2%)	2 (4%)		1 (2%)
Arteriole, Inflammation		1 (2%)		

---

\*\*\* END OF REPORT \*\*\*